Page 1

BB Biotech Media release of July 23 , 2021 Interim report of BB Biotech AG as at June 30 , 2021 Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps Inflation moved higher during the second quarter as the economic recovery gathered steam , triggering temporary outflows of investor capital from growth sectors . Central banks signaled that the rise in inflation would be short - lived , after which capital began to flow back into tech and healthcare stocks . BB Biotech shares returned 5.8 % in CHF and 6.1 % in EUR in the second quarter of 2021. Their total return for the first half of 2021 including the dividend payout was 22.2 % in CHF and 21.3 % in EUR . BB Biotech took profits in Alexion , Biogen , Moderna , Agios and other positions during the second quarter and reinvested the proceeds in more recently established positions such as Fate Therapeutics , Revolution Medicines , Relay Therapeutics , Essa Pharma and Molecular Templates . The biotech sector's prominent role in developing solutions to the pandemic continues to fuel general momentum , which could lead to further stock listings and rights issues , as well as take - overs at attractive prices . Major regulatory decisions for several companies in BB Biotech's portfolio are also expected in the second half of the year . During the second quarter , most indices ' total returns reached high single digits such as the S & P 8.6 % , the Dow Jones 5.1 % and the Nasdaq Composite Index 9.7 % ( all values in USD ) . Some European markets indexes such as the EuroStoxx 50 ( + 5.3 % , in EUR ) and the Dax ( + 3.5 % , in EUR ) were slightly less up , with the Swiss SPI Index ( + 9.5 % , in CHF ) in line to the US markets . Healthcare markets rebounded from the April sell - off to close the second quarter in positive territory . Driven by the SARS - CoV - 2 vaccine players , the controversial approval of Aduhelm to treat Alzheimer's disease and substantial value appreciations for many gene editing companies , the broad MSCI World Healthcare Index ( + 9.3 % , in USD ) , and Nasdaq Biotech Index ( + 9.2 % , in USD ) posted impressive gains . BB Biotech's second quarter and half year 2021 performance BB Biotech's share price was 5.8 % in CHF and 6.1 % in EUR during the second quarter 2021. The Net Asset Value ( NAV ) grew 3.3 % in CHF , 4.2 % in EUR and 5.3 % in USD . Consequently , net profit for the second quarter was CHF 129 mn compared to the extraordinary net profit of CHF 1.18 bn for the same period in 2020 . For the first half of 2021 , the total share price return was 22.2 % in CHF and 21.3 % in EUR , including the dividend . This was ahead of the Net Asset Value appreciation of 8.9 % in CHF , 7.3 % in EUR and 4.1 % in USD . This resulted in a net profit of CHF 349 mn for the first half of 2021 compared to the CHF 422 mn figure reported for the same period of last year . Exchange - rate fluctuations in the USD / CHF currency pair contributed first half 2021 performance by approximately 4.8 % . Change to the Board of Directors of BB Biotech AstraZeneca has announced that Dr. Susan Galbraith will be promoted to lead worldwide Oncology Research & Development from initial discovery through late - stage development , consequently , Dr. Galbraith informed BB Biotech that she will resign from the Board of Directors of BB Biotech AG with immediate effect . While the Board regrets the loss of Dr. Galbraith who has already made great contributions as a Board member , the Board fully understands her need to focus on her remarkably consequential new assignment and congratulates her on the new role and wishes Dr. Galbraith all the best in future endeavors . BB Biotech will launch a search for a new candidate for election to the Board of Directors at its next Annual General Meeting . Second quarter 2021 portfolio activity The investment management team focused on our existing smaller and mid cap companies and on the volatile situations such as the SARS - CoV - 2 vaccine updates , the controversial approval of Biogen's Aduhelm and the many clinical trial updates from within our existing portfolio , and no additions were made to the portfolio . After the US Federal Trade Commission cleared AstraZeneca's acquisition of Alexion , Alexion shares traded within the range of the takeover price , after which the investment team sold its entire position in Alexion , locking in the significant profits . Capital released from the Alexion position together with continued profits from Halozyme were allocated to BB Biotech AG www.bbbiotech.com Schwertstrasse 6 CH - 8200 Schaffhausen T +41 52 624 08 45